In the present study, we first studied FBP1 and FBP2 in The Cancer Genome Atlas (TCGA) and found that reduced FBP1 expression was associated with poor overall survival (OS) in GC patients, and validated the prognostic value of FBP1 in in-house GC samples by immunohistochemical (IHC) staining. The gene discussed is FBP2; the disease is gastric cancer.